These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12087092)

  • 1. Role of Dok1 in cell signaling mediated by RET tyrosine kinase.
    Murakami H; Yamamura Y; Shimono Y; Kawai K; Kurokawa K; Takahashi M
    J Biol Chem; 2002 Sep; 277(36):32781-90. PubMed ID: 12087092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
    Besset V; Scott RP; Ibáñez CF
    J Biol Chem; 2000 Dec; 275(50):39159-66. PubMed ID: 10995764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
    Murakami H; Iwashita T; Asai N; Shimono Y; Iwata Y; Kawai K; Takahashi M
    Biochem Biophys Res Commun; 1999 Aug; 262(1):68-75. PubMed ID: 10448070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
    Asai N; Murakami H; Iwashita T; Takahashi M
    J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret.
    Chiariello M; Visconti R; Carlomagno F; Melillo RM; Bucci C; de Franciscis V; Fox GM; Jing S; Coso OA; Gutkind JS; Fusco A; Santoro M
    Oncogene; 1998 May; 16(19):2435-45. PubMed ID: 9627110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.
    Maeda K; Murakami H; Yoshida R; Ichihara M; Abe A; Hirai M; Murohara T; Takahashi M
    Biochem Biophys Res Commun; 2004 Oct; 323(1):345-54. PubMed ID: 15351743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor.
    Hayashi H; Ichihara M; Iwashita T; Murakami H; Shimono Y; Kawai K; Kurokawa K; Murakumo Y; Imai T; Funahashi H; Nakao A; Takahashi M
    Oncogene; 2000 Sep; 19(39):4469-75. PubMed ID: 11002419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin receptor-mediated p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting insulin-stimulated activation of Ras and Akt.
    Wick MJ; Dong LQ; Hu D; Langlais P; Liu F
    J Biol Chem; 2001 Nov; 276(46):42843-50. PubMed ID: 11551902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.
    Kurokawa K; Iwashita T; Murakami H; Hayashi H; Kawai K; Takahashi M
    Oncogene; 2001 Apr; 20(16):1929-38. PubMed ID: 11360177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
    Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
    Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for the specific recognition of RET by the Dok1 phosphotyrosine binding domain.
    Shi N; Ye S; Bartlam M; Yang M; Wu J; Liu Y; Sun F; Han X; Peng X; Qiang B; Yuan J; Rao Z
    J Biol Chem; 2004 Feb; 279(6):4962-9. PubMed ID: 14607833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
    Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.
    Watanabe T; Ichihara M; Hashimoto M; Shimono K; Shimoyama Y; Nagasaka T; Murakumo Y; Murakami H; Sugiura H; Iwata H; Ishiguro N; Takahashi M
    Am J Pathol; 2002 Jul; 161(1):249-56. PubMed ID: 12107109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
    De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
    Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.